Evidence map›Paper›PMID 33624399›Full record

ArticlePediatric blood & cancer2021

Response criteria for intraocular retinoblastoma: RB-RECIST.

Jesse L Berry, Francis L Munier, Brenda L Gallie, Ashley Polski, Sona Shah, Carol L Shields, Dan S Gombos, Kathleen Ruchalski, Christina Stathopoulos, Rachana Shah and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Review
  4. Article
  5. Factors correlated to different patterns of regression of retinoblastoma defined by optical coherence tomography.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  6. Observational
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jesse L BerryThe Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-8907-9100
Francis L MunierJules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Brenda L GallieDepartment of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-9697-9211
Ashley PolskiThe Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-6301-6892
Sona ShahThe Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.
Carol L ShieldsOcular Oncology Service, Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
Dan S GombosDepartment of Head & Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kathleen RuchalskiDepartment of Radiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Christina StathopoulosJules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Rachana ShahCancer and Blood Disease Institute at Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-8445-2172
Rima JubranCancer and Blood Disease Institute at Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-2169-7826
Jonathan W KimThe Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.
Prithvi MruthyunjayaDepartment of Ophthalmology, Stanford Byers Eye Institute, Palo Alto, California, USA.ORCID 0000-0003-1087-9736
Brian P MarrDepartment of Ophthalmology, Columbia University Medical Center, New York, New York, USA.
Matthew W WilsonDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Rachel C BrennanDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-2090-4395
Guillermo L ChantadaHemato-Oncology Service, Hospital JP Garrahan, Buenos Aires, Argentina.ORCID 0000-0002-9375-9336
Murali M ChintagumpalaTexas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
A Linn MurphreeThe Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Ophthalmic Therapeutics Engineering CoreP30EY029220 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Mahnaz Shahidi · 2018 to 2026
$6.5M
Development of a surrogate liquid biopsy from the aqueous humor in retinoblastoma eyes.K08CA232344 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI BERRY, JESSE L · 2018 to 2022
$1.1M
NCI NIH HHS K08 CA232344NCI NIH HHS P30 CA014089NEI NIH HHS P30 EY029220
6 · The paper itself

Abstract

Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response-such as progression-free survival-to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

Indexed as

Response Evaluation Criteria in Solid TumorsHumansMultimodal ImagingRetinal NeoplasmsRetinoblastomaclinical trialsimagingocular oncologyresponse criteriaretinoblastomaultrasonography

Identifiers

PMID33624399
PMCPMC8049511

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.